Next Article in Journal
COVID-19 Infection Diagnosis: Potential Impact of Isothermal Amplification Technology to Reduce Community Transmission of SARS-CoV-2
Previous Article in Journal
Changes in the 3D Corneal Structure and Morphogeometric Properties in Keratoconus after Corneal Collagen Crosslinking
Open AccessCommunication

Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures

1
Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark
2
Department of Nuclear Medicine, Odense University Hospital, 5000 Odense, Denmark
3
Open Patient data Explorative Network (OPEN), Odense University Hospital, 5000 Odense, Denmark
4
Department of Oncology, Odense University Hospital, 5000 Odense, Denmark
5
Centre for Innovative Medical Technology, Odense University Hospital, 5000 Odense, Denmark
6
Centre for Personalized Response Monitoring in Oncology, Odense University Hospital, 5000 Odense, Denmark
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Diagnostics 2020, 10(6), 398; https://doi.org/10.3390/diagnostics10060398
Received: 26 May 2020 / Revised: 6 June 2020 / Accepted: 8 June 2020 / Published: 11 June 2020
(This article belongs to the Section Medical Imaging)
This study aimed to compare the prognostic value of quantitative measures of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) for the response monitoring of patients with metastatic breast cancer (MBC). In this prospective study, 22 patients with biopsy-verified MBC diagnosed between 2011 and 2014 at Odense University Hospital (Denmark) were followed up until 2019. A dual-time-point FDG-PET/CT scan protocol (1 and 3 h) was applied at baseline, when MBC was diagnosed. Baseline characteristics and quantitative measures of maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), corrected SUVmean (cSUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and corrected TLG (cTLG) were collected. Survival time was analyzed using the Kaplan–Meier method and was regressed on MTV, TLG, and cTLG while adjusting for clinicopathological characteristics. Among the 22 patients included (median age: 59.5 years), 21 patients (95%) died within the follow-up period. Median survival time was 29.13 months (95% Confidence interval: 20.4–40 months). Multivariable Cox proportional hazards regression analyses of survival time showed no influence from the SUVmean, cSUVmean, or SUVmax, while increased values of MTV, TLG, and cTLG were significantly associated with slightly higher risk, with hazard ratios ranging between 1.0003 and 1.004 (p = 0.007 to p = 0.026). Changes from 1 to 3 h were insignificant for all PET measures in the regression model. In conclusion, MTV and TLG are potential prognostic markers for overall survival in MBC patients. View Full-Text
Keywords: metastatic breast cancer; FDG-PET/CT; metabolic tumor volume; prognostic value; total lesion glycolysis metastatic breast cancer; FDG-PET/CT; metabolic tumor volume; prognostic value; total lesion glycolysis
Show Figures

Figure 1

MDPI and ACS Style

Naghavi-Behzad, M.; Bjerg Petersen, C.; Vogsen, M.; Braad, P.-E.; Grubbe Hildebrandt, M.; Gerke, O. Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures. Diagnostics 2020, 10, 398.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop